含苯甲醚结构的2,4,5,6-四取代嘧啶衍生物的合成及抗增殖活性研究

doi:10.6023/cjoc202201048

有机化学 ›› 2022, Vol. 42 ›› Issue (6): 1677-1686.DOI: 10.6023/cjoc202201048 上一篇下一篇

研究论文

含苯甲醚结构的2,4,5,6-四取代嘧啶衍生物的合成及抗增殖活性研究

高潮^a^,^b, 司晓杰^a^,^b, 池玲玲^a^,^b, 王浩^a^,^b, 戴洪林^a^,^b, 刘丽敏^a^,^b, 汪正捷^a^,^b, 张洋^a^,^b, 王涛^a^,^b, 周耀传^a, 郑甲信^a^,^b, 可钰^a^,^b^,^c^,^d^,^*(), 刘宏民^a^,^b^,^c^,^d^,^*(), 张秋荣^a^,^b^,^c^,^d^,^*()

a 郑州大学药学院郑州 450001
b 新药创制与药物安全性评价河南省协同创新和药物质量与评价中心郑州 450001
c 郑州大学省部共建食管癌防治国家重点实验室郑州 450052
d 教育部药物制备关键技术重点实验室郑州 450001

收稿日期:2022-01-28 修回日期:2022-03-08 发布日期:2022-03-21
通讯作者: 可钰, 刘宏民, 张秋荣
基金资助:
国家自然科学基金(U21A20416); 省部共建食管癌防治国家重点实验室资助的开放基金(K2020000X)

Synthesis and Antiproliferative Activity of 2,4,5,6-Tetrasubstituted Pyrimidine Derivatives Containing Anisole

Chao Gao^a^,^b, Xiaojie Si^a^,^b, Lingling Chi^a^,^b, Hao Wang^a^,^b, Honglin Dai^a^,^b, Limin Liu^a^,^b, Zhengjie Wang^a^,^b, Yang Zhang^a^,^b, Tao Wang^a^,^b, Yaochuan Zhou^a, Jiaxin Zheng^a^,^b, Yu Ke^a^,^b^,^c^,^d(), Hongmin Liu^a^,^b^,^c^,^d(), Qiurong Zhang^a^,^b^,^c^,^d()

a School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001
b Collaborative Innovation Center of New Drug Research & Quality and Safety Evaluation, Zhengzhou 450001
c State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou 450052
d Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Zhengzhou 450001

Received:2022-01-28 Revised:2022-03-08 Published:2022-03-21
Contact: Yu Ke, Hongmin Liu, Qiurong Zhang
Supported by:
National Natural Science Foundation of China(U21A20416); Opening Fund from State Key Laboratory of Esophageal Cancer Prevention & Treatment(K2020000X)

文章分享

1. 221677S.pdf(9574KB)

摘要/Abstract

为了寻找高效的新型抗肿瘤药物, 设计并合成了一系列含苯甲醚结构的2,4,5,6-四取代嘧啶衍生物, 并采用噻唑蓝(MTT)法测定了目标化合物对PC-3(人前列腺癌细胞)、MGC-803(人胃癌细胞)、MCF-7(人乳腺癌细胞)、HGC-27(人未分化胃癌细胞)四种人肿瘤细胞的抗增殖活性. 结果显示部分化合物表现出中度至强效的抗增殖活性, 其中5-乙基- 6-((4-甲氧基苯基)硫代)-N⁴-(3,4,5-三甲氧基苯基)嘧啶-2,4-二胺(14t)对HGC-27细胞具有最好的抗增殖活性, IC₅₀值为(0.98±0.12) μmol•L^–1, 抗增殖活性明显优于阳性对照5-氟尿嘧啶. 进一步抗肿瘤机制研究表明, 化合物14t可以显著抑制HGC-27细胞的克隆形成和迁移, 诱导细胞凋亡. 同时化合物14t可以下调抗凋亡蛋白Bcl-2的表达, 上调促凋亡蛋白Bax和P53的表达.

关键词: 嘧啶, 苯甲醚, 合成, 抗增殖活性

In order to find efficient new anti-tumor drugs, a series of 2,4,5,6-tetrasubstituted pyrimidine derivatives containing anisole structure were designed, synthesized and evaluated for antiproliferative activity against four human cancer cell lines of PC-3, MGC-803, MCF-7 and HGC-27 using methyl thiazolyl tetrazolium (MTT) assay. Most of compounds displayed moderate to excellent antiproliferative activity against the four human tumor cell lines, among which the compound 5-ethyl-6- ((4-methoxyphenyl)thio)-N⁴-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine (14t) showed the best antiproliferative activity on HGC-27 cells, with IC₅₀value of (0.98±0.12) μmol•L^–1, the antiproliferative activity is significantly better than that of the positive control 5-fluorouracil. Further research on anti-tumor mechanism showed that compound 14t could significantly inhibit the colony formation and migration of HGC-27 cells and induce apoptosis. At the same time, compound 14t can down-regulate the expression of anti-apoptotic protein Bcl-2 and up-regulate the expression of pro-apoptotic proteins Bax and P53.

Key words: pyrimidine, anisole, synthesis, antiproliferative activity

引用此文

高潮, 司晓杰, 池玲玲, 王浩, 戴洪林, 刘丽敏, 汪正捷, 张洋, 王涛, 周耀传, 郑甲信, 可钰, 刘宏民, 张秋荣. 含苯甲醚结构的2,4,5,6-四取代嘧啶衍生物的合成及抗增殖活性研究[J]. 有机化学, 2022, 42(6): 1677-1686.

Chao Gao, Xiaojie Si, Lingling Chi, Hao Wang, Honglin Dai, Limin Liu, Zhengjie Wang, Yang Zhang, Tao Wang, Yaochuan Zhou, Jiaxin Zheng, Yu Ke, Hongmin Liu, Qiurong Zhang. Synthesis and Antiproliferative Activity of 2,4,5,6-Tetrasubstituted Pyrimidine Derivatives Containing Anisole[J]. Chinese Journal of Organic Chemistry, 2022, 42(6): 1677-1686.

导出引用 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

分享此文

图/表 10

Figure 1. Structures of some pyrimidine derivatives and derivatives containing anisole

Figure 2. Design strategy for 2,4,5,6-tetrasubstituted pyrimidine derivatives containing anisole

Scheme 1. Synthetic route of compounds 14a~14t

Compd.	R	IC₅₀^a/(μmol·L^–1)
Compd.	R	PC-3	MGC-803	MCF-7	HGC-27
14a	—	>50	>50	>50	>50
14b	2-F	15.70±1.19	25.36±0.76	27.67±1.44	30.96±1.49
14c	3-F	19.03±0.99	39.79±1.60	45.20±1.66	37.87±1.44
14d	4-F	20.67±1.03	44.66±1.65	>50	35.73±1.55
14e	2-Cl	11.13±1.05	20.68±1.32	23.65±1.64	14.32±1.16
14f	3-Cl	>50	24.89±1.40	41.63±1.62	>50
14g	4-Cl	26.58±1.42	>50	27.72±1.44	49.93±1.60
14h	2-Br	10.08±1.00	14.59±1.16	33.74±1.53	12.22±1.09
14i	3-Br	>50	>50	>50	>50
14j	4-Br	12.39±0.97	17.99±1.25	35.95±1.14	28.75±1.46
14k	2-CH₃	>50	40.01±1.60	>50	>50
14l	3-CH₃	>50	>50	>50	>50
14m	4-CH₃	>50	>50	>50	>50
14n	2-OCH₃	5.22±0.72	10.06±1.00	7.79±0.89	5.15±0.71
14o	3-OCH₃	8.41±0.92	32.69±1.51	17.53±1.24	27.55±1.44
14p	4-OCH₃	10.70±1.03	18.18±1.26	15.36±1.19	11.75±1.07
14q	3,4-Cl₂	10.91±1.04	13.77±1.14	6.64±0.88	11.52±1.06
14r	2,4-Cl₂	>50	>50	42.73±1.63	>50
14s	3-Cl-4-F	27.97±0.90	42.36±1.63	29.99±1.48	>50
14t	3,4,5-(OCH₃)₃	5.59±0.75	2.41±0.38	5.94±0.77	0.98±0.12
5-Fu^b	—	6.39±0.71	10.64±1.09	10.23±0.68	7.25±0.72

Table 1. In vitro antiproliferative activity evaluation results of compounds 14a~14t

Compd.	IC₅₀/(μmol·L^–1)
Compd.	GES-1	HEEC
14t	43.98±1.64	>100
5-Fu	13.30±1.12	>100

Table 2. In vitro antiproliferative activity of compound 14t against human normal cells

Figure 3. Effect of compound 14t on colony formation of HGC-27 cells (A) HGC-27 Cell colonies treated with compound 14t at different concentrations; (B) Quantitative analysis of colony formation inhibition rate

Figure 4. In vitro wound healing assay on HGC-27 cells (A) Phase contrast images were obtained by the treatment of compound 14t at indicated concentrations for 0, 12 and 24 h; (B) Quantitative analysis of cell migration rate. Compared with the control group, *P<0.05, **P<0.01, ***P<0.001

Figure 5. Effect of compound 14t on nuclear morphology of HGC-27 cells The arrows in the figure indicate the cells whose nuclei have shrunk or broken

Figure 6. Effect of compound 14t on apoptosis of HGC-27 cells (A) Annexin V-FITC/PI detected apoptosis of HGC-27 cells treated with different concentrations of compound 14t for 48 h; (B) annexin V-FITC/PI detected apoptosis of HGC-27 cells treated with different concentrations of compound 14t for 72 h; (C) quantitative analysis of apoptosis cells of HGC-27 for 48 h; (D) quantitative analysis of apoptosis cells of HGC-27 for 72 h (Compared with the control group, ***P<0.001)

Figure 7. Effect of compound 14t on apoptosis-related proteins (A) Changes in protein expression after treatment with different concentrations of compound 14t. GAPDH is the reference protein. (B, C, and D) quantitative analysis diagrams of each protein. Compared with the control group, *P<0.05, **P<0.01, ***P<0.001

参考文献 28

[1]	Sung, H.; Ferlay, J.; Siegel, R. L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. CA Cancer J Clin. 2021, 71, 209. doi: 10.3322/caac.21660
[2]	Mao, J. J.; Pillai, G. G.; Andrade, C. J.; Ligibel, J. A.; Basu, P.; Cohen, L.; Khan, I. A.; Mustian, K. M.; Puthiyedath, R.; Dhiman, K. S.; Lao, L.; Ghelman, R.; Caceres Guido, P.; Lopez, G.; Gallego-Perez, D. F.; Salicrup, L. A. CA Cancer J Clin. 2022, 72, 144. doi: 10.3322/caac.21706
[3]	Tilaoui, M.; Ait Mouse, H.; Zyad, A. Front Pharmacol. 2021, 12, 719694. doi: 10.3389/fphar.2021.719694
[4]	Gu, X.; Huang, Z.; Ren, Z.; Tang, X.; Xue, R.; Luo, X.; Peng, S.; Peng, H.; Lu, B.; Tian, J.; Zhang, Y. J. Med. Chem. 2017, 60, 928. doi: 10.1021/acs.jmedchem.6b01075
[5]	Meng, Y.; Li, E.; Zhang, Y.; Liu, S.; Bao, C.; Yang, P.; Zhang, L.; Zhang, D.; Wang, J.; Chen, Y.; Li, N.; Xin, J.; Zhao, P.; Ke, Y.; Zhang, Q.; Liu, H. Chin. J. Org. Chem. 2019, 39, 2541. (in Chinese) doi: 10.6023/cjoc201903022
	( 孟娅琪, 李二冬, 张洋, 刘栓, 包崇男, 杨鹏, 张路野, 张丹青, 王继宽, 陈雅欣, 栗娜, 辛景超, 赵培荣, 可钰, 张秋荣, 刘宏民, 有机化学, 2019, 39, 2541.)
[6]	Ma, L. Y.; Zheng, Y. C.; Wang, S. Q.; Wang, B.; Wang, Z. R.; Pang, L. P.; Zhang, M.; Wang, J. W.; Ding, L.; Li, J.; Wang, C.; Hu, B.; Liu, Y.; Zhang, X. D.; Wang, J. J.; Wang, Z. J.; Zhao, W.; Liu, H. M. J. Med. Chem. 2015, 58, 1705. doi: 10.1021/acs.jmedchem.5b00037 pmid: 25610955
[7]	Guillemont, J.; Pasquier, E.; Palandjian, P.; Vernier, D.; Gaurrand, S.; Lewi, P. J.; Heeres, J.; de Jonge, M. R.; Koymans, L. M.; Daeyaert, F. F.; Vinkers, M. H.; Arnold, E.; Das, K.; Pauwels, R.; Andries, K.; de Bethune, M. P.; Bettens, E.; Hertogs, K.; Wigerinck, P.; Timmerman, P.; Janssen, P. A. J. Med. Chem. 2005, 48, 2072. pmid: 15771449
[8]	Wang, L.; Tang, J.; Huber, A. D.; Casey, M. C.; Kirby, K. A.; Wilson, D. J.; Kankanala, J.; Xie, J.; Parniak, M. A.; Sarafianos, S. G.; Wang, Z. Eur. J. Med. Chem. 2018, 156, 652. doi: S0223-5234(18)30595-6 pmid: 30031976
[9]	Kumar, N.; Chauhan, A.; Drabu, S. Biomed. Pharmacother. 2011, 65, 375. doi: 10.1016/j.biopha.2011.04.023
[10]	Tale, R. H.; Rodge, A. H.; Hatnapure, G. D.; Keche, A. P. Bioorg. Med. Chem. Lett. 2011, 21, 4648. doi: 10.1016/j.bmcl.2011.03.062
[11]	Fouda, A. M.; Abbas, H. S.; Ahmed, E. H.; Shati, A. A.; Alfaifi, M. Y.; Elbehairi, S. E. I. Molecules 2019, 24, 1080. doi: 10.3390/molecules24061080
[12]	Shaaban, O. G.; Issa, D. A. E.; El-Tombary, A. A.; Abd El Wahab, S. M.; Abdel Wahab, A. E.; Abdelwahab, I. A. Bioorg. Chem. 2019, 88, 102934. doi: 10.1016/j.bioorg.2019.102934
[13]	Cassidy, J.; Clarke, S.; Diaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Rittweger, K.; Gilberg, F.; Saltz, L. Br. J. Cancer 2011, 105, 58. doi: 10.1038/bjc.2011.201
[14]	Passaro, A.; Guerini-Rocco, E.; Pochesci, A.; Vacirca, D.; Spitaleri, G.; Catania, C. M.; Rappa, A.; Barberis, M.; de Marinis, F. Pharmacol. Res. 2017, 117, 406. doi: 10.1016/j.phrs.2017.01.003
[15]	Finlay, M. R.; Anderton, M.; Ashton, S.; Ballard, P.; Bethel, P. A.; Box, M. R.; Bradbury, R. H.; Brown, S. J.; Butterworth, S.; Campbell, A.; Chorley, C.; Colclough, N.; Cross, D. A.; Currie, G. S.; Grist, M.; Hassall, L.; Hill, G. B.; James, D.; James, M.; Kemmitt, P.; Klinowska, T.; Lamont, G.; Lamont, S. G.; Martin, N.; McFarland, H. L.; Mellor, M. J.; Orme, J. P.; Perkins, D.; Perkins, P.; Richmond, G.; Smith, P.; Ward, R. A.; Waring, M. J.; Whittaker, D.; Wells, S.; Wrigley, G. L. J. Med. Chem. 2014, 57, 8249. doi: 10.1021/jm500973a
[16]	Cross, D. A.; Ashton, S. E.; Ghiorghiu, S.; Eberlein, C.; Nebhan, C. A.; Spitzler, P. J.; Orme, J. P.; Finlay, M. R.; Ward, R. A.; Mellor, M. J.; Hughes, G.; Rahi, A.; Jacobs, V. N.; Red Brewer, M.; Ichihara, E.; Sun, J.; Jin, H.; Ballard, P.; Al-Kadhimi, K.; Rowlinson, R.; Klinowska, T.; Richmond, G. H.; Cantarini, M.; Kim, D. W.; Ranson, M. R.; Pao, W. Cancer Discovery 2014, 4, 1046. doi: 10.1158/2159-8290.CD-14-0337
[17]	Jabbour, E. Am. J. Hematol. 2016, 91, 59. doi: 10.1002/ajh.24249 pmid: 26769227
[18]	Kategaya, L.; Di Lello, P.; Rougé, L.; Pastor, R.; Clark, K. R.; Drummond, J.; Kleinheinz, T.; Lin, E.; Upton, J.-P.; Prakash, S.; Heideker, J.; McCleland, M.; Ritorto, M. S.; Alessi, D. R.; Trost, M.; Bainbridge, T. W.; Kwok, M. C. M.; Ma, T. P.; Stiffler, Z.; Brasher, B.; Tang, Y.; Jaishankar, P.; Hearn, B. R.; Renslo, A. R.; Arkin, M. R.; Cohen, F.; Yu, K.; Peale, F.; Gnad, F.; Chang, M. T.; Klijn, C.; Blackwood, E.; Martin, S. E.; Forrest, W. F.; Ernst, J. A.; Ndubaku, C.; Wang, X.; Beresini, M. H.; Tsui, V.; Schwerdtfeger, C.; Blake, R. A.; Murray, J.; Maurer, T.; Wertz, I. E. Nature 2017, 550, 534. doi: 10.1038/nature24006
[19]	Di Lello, P.; Pastor, R.; Murray, J. M.; Blake, R. A.; Cohen, F.; Crawford, T. D.; Drobnick, J.; Drummond, J.; Kategaya, L.; Kleinheinz, T.; Maurer, T.; Rouge, L.; Zhao, X.; Wertz, I.; Ndubaku, C.; Tsui, V. J. Med. Chem. 2017, 60, 10056. doi: 10.1021/acs.jmedchem.7b01293
[20]	Modranka, J.; Drogosz-Stachowicz, J.; Pietrzak, A.; Janecka, A.; Janecki, T. Eur. J. Med. Chem. 2021, 219, 113429. doi: 10.1016/j.ejmech.2021.113429
[21]	Barghash, R. F.; Eldehna, W. M.; Kovalova, M.; Vojackova, V.; Krystof, V.; Abdel-Aziz, H. A. Eur. J. Med. Chem. 2022, 227, 113952. doi: 10.1016/j.ejmech.2021.113952
[22]	Li, J.; Hu, X.; Luo, T.; Lu, Y.; Feng, Y.; Zhang, H.; Liu, D.; Fan, X.; Wang, Y.; Jiang, L.; Wang, Y.; Hao, X.; Shi, T.; Wang, Z. Eur. J. Med. Chem. 2021, 226, 113817. doi: 10.1016/j.ejmech.2021.113817
[23]	Ren, Y.; Ruan, Y.; Cheng, B.; Li, L.; Liu, J.; Fang, Y.; Chen, J. Bioorg. Med. Chem. 2021, 46, 116376. doi: 10.1016/j.bmc.2021.116376
[24]	Ma, J.; Liang, W.; Qiang, Y.; Li, L.; Du, J.; Pan, C.; Chen, B.; Zhang, C.; Chen, Y.; Wang, Q. Cell Commun. Signal. 2021, 19, 122. doi: 10.1186/s12964-021-00804-0
[25]	Fu, S.; Chen, X.; Lo, H. W.; Lin, J. Cancer Lett. 2019, 448, 11. doi: 10.1016/j.canlet.2019.01.026
[26]	Legraverend, M.; Bisagni, E. Tetrahedron Lett. 1985, 26, 2001. doi: 10.1016/S0040-4039(00)98364-3
[27]	Legraverend, M.; Ngongo-Tekam, R. M.; Bisagni, E.; Zerial, A. J Med. Chem. 1985, 28, 1477. pmid: 2995667
[28]	Jansa, P.; Holy, A.; Dracinsky, M.; Kolman, V.; Janeba, Z.; Kostecka, P.; Kmonickova, E.; Zidek, Z. Med. Chem. Res. 2014, 23, 4482. doi: 10.1007/s00044-014-1018-9 pmid: 32214763

含苯甲醚结构的2,4,5,6-四取代嘧啶衍生物的合成及抗增殖活性研究

Synthesis and Antiproliferative Activity of 2,4,5,6-Tetrasubstituted Pyrimidine Derivatives Containing Anisole

RichHTML

PDF

补充材料

可视化

摘要/Abstract

引用此文

分享此文

图/表 10

参考文献 28

相关文章 15

编辑推荐

相关统计

本文评价

[1]	张向阳, 吴庆林, 王菲菲, 申有名, 唐裕才. 一种以2-羟基-N,N-二甲基苄胺为新识别基团的钯离子近红外荧光探针及其细胞成像[J]. 有机化学, 2022, 42(6): 1786-1791.
[2]	陈思鸿, 许佳敏, 李月媚, 彭宝茹, 罗凌玉, 冯慧烨, 陈兆华, 汪朝阳. 基于有机小分子的聚集诱导猝灭(ACQ)-聚集诱导发射(AIE)转换研究进展[J]. 有机化学, 2022, 42(6): 1651-1666.
[3]	刘斌凯, 滕坤旭, 牛丽亚, 杨清正. 氟硼二吡咯(BODIPY)荧光染料的合成研究进展[J]. 有机化学, 2022, 42(5): 1265-1285.
[4]	雍灿, 李芸, 毕涛, 陈国凤, 郑东霞, 王周玉, 张园园. 基于D-半乳糖衍生的小分子半乳糖凝集素抑制剂的合成及活性研究进展[J]. 有机化学, 2022, 42(5): 1307-1325.
[5]	张智鑫, 翟彤仪, 朱伯汉, 钱鹏程, 叶龙武. 无金属催化炔酰胺分子内[4+2]环化反应合成四氢吲哚衍生物[J]. 有机化学, 2022, 42(5): 1501-1508.
[6]	王馨瑶, 张晴晴, 刘书扬, 李敏, 李海芳, 段春迎, 金云鹤. 可见光诱导无金属条件下交叉脱氢偶联反应合成醌类苄基化衍生物[J]. 有机化学, 2022, 42(5): 1443-1452.
[7]	姚婷, 李佳燕, 王佳明, 赵常贵. 氮杂环卡宾催化构筑含七元环结构的研究进展[J]. 有机化学, 2022, 42(4): 925-944.
[8]	刘文启, 沈振陆, 徐森苗. 三苯基砷/铱催化的非活化一级碳氢键的双硼化反应合成1,1-偕二硼烷[J]. 有机化学, 2022, 42(4): 1101-1110.
[9]	韩群, 徐坤, 田发宁, 黄胜阳, 曾程初. 一种利用酰胺基转移反应脱除酰基保护基的实用方法[J]. 有机化学, 2022, 42(4): 1123-1128.
[10]	龚婷婷, 陈智斌, 刘妙昌, 成江. 2-苯并呋喃-1(3H)-酮的合成研究进展[J]. 有机化学, 2022, 42(4): 1085-1100.
[11]	李可欣, 杨庆远, 张鹏鹏, 张武元. 过氧化氢原位生成驱动过氧合酶催化反应研究进展[J]. 有机化学, 2022, 42(3): 732-741.
[12]	徐萌萌, 蔡泉. 2-吡喃酮的催化不对称Diels-Alder反应研究进展[J]. 有机化学, 2022, 42(3): 698-713.
[13]	王立花, 公绪顺, 雷婷, 江世智. 黄烷酮的不对称合成研究进展[J]. 有机化学, 2022, 42(3): 758-769.
[14]	孔媛芳, 杨彬, 庄严, 张京玉, 孙德梅, 董春红. 基于二肽基肽酶4 (DPP-4)靶点设计的五种降糖活性杂环合成及构效关系研究进展[J]. 有机化学, 2022, 42(3): 770-784.
[15]	罗享豪, 谢益碧, 黄年玉, 王龙. 基于原位捕获异腈的Ugi四组分反应及其后修饰串联反应: 一锅法合成含氮杂环化合物[J]. 有机化学, 2022, 42(3): 838-846.